Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of Three Global Trials

Journal:
Journal of the American College of Cardiology
Published:
DOI:
10.1016/j.jacc.2025.08.039
Affiliations:
23
Authors:
24
Go to article
Institutions Authors Share
Brigham and Women's Hospital (BWH), United States of America (USA)
5.000000
 0.21
Bayer, Germany
2.000000
 0.08
University General Hospital Attikon, Greece
2.000000
 0.08
University of Glasgow, United Kingdom (UK)
2.000000
 0.08
Bayer S.A., Brazil
1.000000
 0.04
University Medical Center Groningen (UMCG), RUG, Netherlands
1.000000
 0.04
Bayer Plc, United Kingdom (UK)
1.000000
 0.04
Michigan Medicine, U-M, United States of America (USA)
1.000000
 0.04
Centre d'investigation clinique Plurithématique de Nancy (CIC-P Nancy), France
1.000000
 0.04
Azienda Ospedaliera Papa Giovanni XXIII, Italy
1.000000
 0.04
Hospital Universitario 12 de Octubre, Spain
1.000000
 0.04
DZHK Partner Site Berlin, Germany
1.000000
 0.04
Northwestern University (NU), United States of America (USA)
1.000000
 0.04
Steno Diabetes Center Copenhagen (SDCC), Denmark
0.500000
 0.02
University of Copenhagen (UCPH), Denmark
0.500000
 0.02
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)
0.500000
 0.02
CPC Clinical Research, United States of America (USA)
0.500000
 0.02
National Heart Centre Singapore (NHCS), Singapore
0.500000
 0.02
Duke-NUS Medical School, Singapore
0.500000
 0.02
Indiana University Indianapolis (IU Indianapolis), United States of America (USA)
0.500000
 0.02
Richard L. Roudebush VA Medical Center, United States of America (USA)
0.500000
 0.02
Interested in Cardiovascular Medicine and Haematology?